Alumis Inc.: Precision Therapies for Immune-Mediated Diseases – Recent Achievements and Upcoming Milestones
Alumis Inc., a clinical-stage biopharmaceutical company, recently reported its financial results for the year ended December 31, 2024, and shared updates on its latest achievements and upcoming milestones. The company is focused on developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases.
Psoriasis Treatment Advancements
At the American Academy of Dermatology (AAD) 2025 meeting, Alumis presented Phase 2 STRIDE OLE 52-week data for its next-generation oral TYK2 inhibitor, ESK-001. The data demonstrated robust long-term clinical responses and well-tolerated treatment. The Phase 3 ONWARD program data readout is now expected in the first quarter of 2026.
MS Therapy Development
Additionally, at the ACTRIMS 2025 conference, Alumis presented Phase 1 clinical data for its first-in-class oral TYK2 inhibitor, A-005. The study showed its ability to cross the blood-brain barrier and was well tolerated. The Phase 2 trial in Multiple Sclerosis is scheduled to begin in the second half of 2025.
Merger Agreement with ACELYRIN
Alumis also announced a merger agreement with ACELYRIN Therapeutics. The combined company will have a differentiated late-stage portfolio of therapies and a strong balance sheet. The merger is expected to close in the second quarter of 2025.
Impact on Patients and the World
For patients, these advancements in psoriasis and MS treatments represent potential new options for managing these chronic conditions. ESK-001’s robust long-term clinical responses and well-tolerated treatment could offer a significant improvement over existing therapies. A-005’s ability to cross the blood-brain barrier and its well-tolerated Phase 1 data suggest a potential breakthrough in MS treatment.
On a larger scale, the merger with ACELYRIN could lead to accelerated development and commercialization of these innovative therapies. A stronger balance sheet and a broader portfolio could also enable Alumis to explore new collaborations and partnerships, further expanding its impact on the biopharmaceutical industry.
Conclusion
Alumis Inc.’s recent achievements and upcoming milestones demonstrate its commitment to developing precision therapies for immune-mediated diseases. The potential advancements in psoriasis and MS treatments, as well as the merger with ACELYRIN, could significantly improve the lives of patients and contribute to the ongoing evolution of the biopharmaceutical industry.
- Alumis presented Phase 2 STRIDE OLE 52-week data for ESK-001 at AAD 2025, showing robust long-term responses and well-tolerated treatment.
- Phase 3 ONWARD program data readout for ESK-001 is expected in Q1 2026.
- A-005, a first-in-class oral TYK2 inhibitor, demonstrated ability to cross blood-brain barrier and was well tolerated in Phase 1 data.
- Phase 2 trial for A-005 in MS is scheduled to begin in 2H 2025.
- Alumis announced merger agreement with ACELYRIN, expected to close in Q2 2025.
- These advancements represent potential new options for managing chronic conditions and could significantly impact the biopharmaceutical industry.
